- Early oseltamivir administration (
Why this matters
- Oseltamivir administration should be considered for reducing pneumonia complications in patients age
- Consult ECDC guidance on antiviral usage in influenza.
- 137 children; mean age, 4.39 years (standard deviation, +3.5; range, 1 month-15 years).
- 35.0% were 2-5 years old, and 32.1%, were 5-9 years old.
- 39.4% (54) had underlying pneumonia.
- Clinical and laboratory characteristics associated with pneumonia:
- Frequent cough: 90.7% (P=.001),
- C-reactive protein: 18.1±18.0 (P=.004).
- Patients ages 0-4 years (P=.002) and 5-9 years (P=.014) were most likely to receive oseltamivir
- No differences noted by sex, age, underlying conditions, preadmission antibiotics, or recent influenza vaccine receipt in patients with/without pneumonia.
- Logistic regression associated pneumonia risk with:
- Early oseltamivir: OR, 0.108 (P=.000); and
- Frequent cough: OR, 2.153 (P=.005).
- Retrospective, observational study assessing clinical, laboratory findings linked to increased influenza B virus-associated pneumonia in hospitalized Chinese children, November 2017-April 2018
- Funding: None disclosed.
- Retrospective, observational.
- Limited generalizability.